PDCD1 and lung carcinoma: Another study by Yang et al. (Yang X. et al., 2022) analyzed the results of lung cancer patients with brain metastases and found that PD-1/PD-L1 inhibitors significantly improved the treatment efficacy, prolonging OS and PFS compared to chemotherapy.